背景
乳腺癌是发病率和死亡率最高的恶性肿瘤之一。许多有效的抗乳腺癌药物正在从天然产物的开发中衍生出来。Voacamine (VOA) 是从Voacanga africana Stapf 中分离出来的一种双吲哚生物碱,具有多种药理和生物活性。
目的
在这项研究中,我们研究了 VOA 对乳腺癌细胞的功效,并阐明了体外和体内的潜在机制。
方法
使用人乳腺癌细胞系MCF-7和小鼠乳腺癌细胞系4T1来研究VOA的潜在抗癌机制。通过MTT、集落形成、细胞增殖和伤口愈合迁移测定来检测增殖。利用流式细胞术测定活性氧 (ROS) 细胞周期、细胞凋亡和线粒体膜电位的水平。通过蛋白质印迹分析靶蛋白。通过 AutoDock 进行分子对接并评分。建立小鼠皮下癌模型,评价其体内抗癌作用。
结果
我们的结果表明,VOA选择性抑制乳腺癌MCF-7和4T1细胞增殖,IC 50值分别为0.99和1.48 μM,并显着抑制肿瘤细胞的迁移和集落形成。此外,细胞周期被阻滞在 S 期,CDK2、Cyclin A 和 Cyclin E 的表达水平降低。此外,暴露于 VOA 会剂量依赖性地导致线粒体膜电位 (Δψ m )的损失和积累。活性氧(ROS)的产生,导致内在细胞凋亡途径的启动。Western blot 分析揭示,VOA 显着激活线粒体相关细胞凋亡,并通过调节两种肿瘤细胞系中的相关蛋白表达水平,明显抑制 PI3K/Akt/mTOR 通路。在荷瘤小鼠模型中,给予 VOA 剂量依赖性地抑制肿瘤生长,且不会引起明显的毒性。
结论
这些发现揭示了VOA通过激活线粒体相关凋亡信号通路和抑制PI3K/Akt/mTOR信号通路促进乳腺癌细胞凋亡的新特性,并显着减小肿瘤大小,且未检测到明显的毒性。总之,目前的结果表明,VOA 可能是一种令人鼓舞的治疗乳腺癌的候选药物,展示了一种从天然成分中开发独特药物的有效方法。
"点击查看英文标题和摘要"
Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K/Akt/mTOR signaling pathway by voacamine suppress breast cancer progression
Background
Breast cancer is one of the malignant tumors with the highest morbidity and mortality rate. Numerous efficient anti-breast cancer drugs are being derived from the development of natural products. Voacamine (VOA), a bisindole alkaloid isolated from Voacanga africana Stapf, possesses various pharmacological and biological activities.
Purpose
In this study, we investigated the efficacy of VOA against breast cancer cells and elucidated the underlying mechanisms in vitro and in vivo.
Methods
Human breast cancer cell line MCF-7 and mouse breast cancer cell line 4T1 were used to study the underlying anti-cancer mechanisms of VOA. The proliferation was detected by MTT, colony formation, cell proliferation and wound-healing migration assays. Flow cytometry was utilized to determine the level of reactive oxygen species (ROS) cell-cycle, apoptosis and mitochondrial membrane potential. The target proteins were analyzed by Western blot. Molecular docking was performed and scored by AutoDock. Subcutaneous cancer models in mice were established to evaluate the anticancer effects in vivo.
Result
Our results demonstrated that VOA selectively suppressed breast cancer MCF-7 and 4T1 cells proliferation with IC50 values of 0.99 and 1.48 μM, and significantly inhibited the migration and colony formation of tumor cells. Furthermore, the cell cycle was arrested in the S phase with the decreased expression levels of CDK2, Cyclin A and Cyclin E. Additionally, exposure to VOA dose-dependently brought about dose-dependently the loss of mitochondrial membrane potential (Δψm) and amassment of reactive oxygen species (ROS), resulting in the initiation of the intrinsic apoptotic pathway. Western blot analysis unveiled that VOA significantly activated mitochondrial-associated apoptosis and obviously suppress the PI3K/Akt/mTOR pathway via modulation of related protein expression levels in both tumor cell lines. In tumor-bearing mouse models, administration of VOA dose-dependently inhibited the tumor growth without causing apparent toxicities.
Conclusion
These findings revealed the novel properties of VOA in promoting apoptosis of breast cancer cells by activating mitochondrial-associated apoptosis signaling pathway and inhibiting PI3K/Akt/mTOR signaling pathway and significantly decreasing tumor size without detecting appreciable toxicity. In summary, the present results demonstrated VOA could be an encouraging drug candidate to cure breast cancer, exhibiting an effective method to exploit unique drugs from natural components.